Semaglutide Treatment On Coronary Progression

NCT03985384 on ClinicalTrials.gov · last registry update 2023-10-05

Finished 27 December 2022, after enrolling 140 people. Primary outcome, as filed: Rate of change in non-calcified plaque volume. semaglutide is already approved in the US for cardiovascular disease and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Sponsor type: Other
Enrollment: 140
Started: 2019-04-30
Primary completion: 2022-12-27 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Rate of change in non-calcified plaque volume

Conditions studied

Type 2 Diabetes · Coronary Artery Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.